Phase 1 Study of Oral TP-1454

Sponsor
Sumitomo Pharma Oncology, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04328740
Collaborator
(none)
44
9
2
38.8
4.9
0.1

Study Details

Study Description

Brief Summary

This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors, alone and in combination with Ipilimumab and Nivolumab.

Detailed Description

Primary Objectives During Dose Escalation:
  • To establish the MTD and/or Recommended Phase 2 Dose (RP2D) of orally administered TP-1454 monotherapy in patients with advanced metastatic solid tumors

  • To establish the MTD and/or RP2D of orally administered TP-1454 in combination with ipilimumab and nivolumab in patients with advanced/ metastatic renal cell carcinoma (RCC) and patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC), who are eligible per FDA approval of ipilimumab and nivolumab by indication for the protocol- defined regimen

Secondary Objectives During Dose Escalation:
  • To establish the pharmacokinetic (PK) profile of orally administered TP-1454 alone and in combination with ipilimumab and nivolumab

  • To observe patients for any evidence of antitumor activity of TP 1454 alone and in combination with ipilimumab and nivolumab by objective radiographic assessment

  • To assess the safety and tolerability of oral TP-1454 administered as monotherapy and in combination with ipilimumab and nivolumab in the defined patient populations

Primary Objectives During Dose Expansion:
  • To evaluate the preliminary antitumor activity, by objective radiographic assessment, of TP-1454 in combination with ipilimumab and nivolumab in patients with mNSCLC expressing PD-L1 (≥1% as determined by an FDA-approved test) with no EGFR or ALK genomic tumor aberrations

  • To establish the RP2D of orally administered TP-1454 in combination with ipilimumab and nivolumab in the defined patient population

Secondary Objectives During Dose Expansion:

• To assess the safety and tolerability of oral TP-1454 in combination with ipilimumab and nivolumab in the defined patient population

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Open labelOpen label
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 Alone and in Combination With Ipilimumab and Nivolumab
Actual Study Start Date :
Jul 8, 2020
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Monotherapy

TP-1454

Drug: TP-1454 monotherapy
Flat dose once or twice daily, alone

Experimental: Combination Therapy

TP-1454, ipilimumab and nivolumab

Drug: TP-1454 combination therapy
Flat dose once or twice daily, in combination with ipilimumab and nivolumab

Outcome Measures

Primary Outcome Measures

  1. During Dose Escalation: Incidence of dose-limiting toxicities (DLTs) [21 or 28 days]

    A DLT is defined as a drug-related toxicity that is observed to occur within the first 21 or 28 days of treatment depending on which arm the patient is enrolled in (monotherapy 28 days; combination 21 days).

  2. During Dose Escalation: Determine maximum tolerated dose (MTD) [28 months]

    MTD will be determined based upon toxicity grades which are defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.

  3. During Dose Escalation: Recommended Ph 2 dose of TP-1454 [28 months]

    To establish the recommended Ph 2 dose (RP2D) for future studies with TP-1454. MTD, PK and PD data to be reviewed.

  4. During Dose Expansion: Determine the preliminary antitumor activity of TP-1454 in combination with ipilimumab and nivolumab [18 months]

    Determine the preliminary antitumor activity of TP-1454 in combination with ipilimumab and nivolumab in terms of objective response rate (ORR) in patients with mNSCLC expressing PD-L1 (≥1% as determined by an FDA-approved test) with no EGFR or ALK genomic tumor aberrations according to RECIST v 1.1 and iRECIST.

  5. During Dose Expansion: Recommended Ph 2 dose of TP-1454 in combination with ipilimumab and nivolumab [18 months]

    Establish the Recommended Ph2 dose for future studies of orally administered TP-1454 in combination with ipilimumab and nivolumab in the defined population. MTD, PK and PD data will be reviewed.

Secondary Outcome Measures

  1. During Dose Escalation: Determine antitumor activity of TP-1454. [28 months]

    Objective radiographic assessment to be performed to determine antitumor activity by Response Evaluation Criteria in Solid Tumors (RECIST criteria v 1.1.

  2. During Dose Expansion: Asses the safety and tolerability of TP-1454 [18 months]

    Assess the safety and tolerability of oral TP-1454 in combination with ipilimumab and nivolumab in the defined patient population. MTD, PK and PD data will be reviewed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Dose Escalation: Have a histologically confirmed diagnosis of a) advanced metastatic or progressive solid tumor, who are refractory to, or intolerant of, established therapy known to provide clinical benefit for their condition (Monotherapy Arm) b) advanced/metastatic renal cell carcinoma (RCC) and patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC), who are eligible per FDA approval of ipilimumab and nivolumab by indication for the protocol- defined regimen (combination arm).

  2. Dose Expansion: Have a histologically confirmed diagnosis of mNSCLC expressing PD-L1 (≥1% as determined by an FDA-approved test) with no EGFR or ALK genomic tumor aberrations, and who are eligible per FDA approval of ipilimumab and nivolumab by indication for the protocol-defined regimen

  3. Naïve to prior treatment with any PD1 or CTLA-4 inhibitor (Combination Arm Only)

  4. Have measurable as outlined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

  6. Have a life expectancy ≥3 months

  7. Be ≥18 years of age

  8. Have a negative pregnancy test (if female of childbearing potential)

  9. Have acceptable liver function:

  10. Bilirubin ≤1.5x upper limit of normal (ULN) (unless associated with Gilbert syndrome)

  11. Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and alkaline phosphatase ≤2.5x ULN* *If liver metastases are present, then ≤ 3x ULN is allowed. ** For patients who will receive ipilimumab and nivolumab in combination with TP-1454 then ≤ 3X ULN is allowed

  12. Have acceptable renal function: calculated creatinine clearance ≥30 mL/min (using Cockcroft Gault formula)

  13. Have acceptable hematologic status:

  14. Granulocyte ≥1500 cells/mm3

  15. Platelet count ≥100,000 (plt/mm3)

  16. Hemoglobin ≥8 g/dL

  17. Have acceptable coagulation status:

  18. Prothrombin time (PT) within 1.5x normal limits

  19. Activated partial thromboplastin time (aPTT) within 1.5x normal limits

  20. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation and for at least 3 months (males) and 6 months (females) after the last study drug dose.

Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

  1. Have read and signed the Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study-related procedure. (In the event that the patient is rescreened for study participation or a protocol amendment alters the care of an ongoing patient, a new ICF must be signed.)
Exclusion Criteria:
  1. New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months or evidence of ischemia on electrocardiogram (ECG) within 14 days prior to Cycle 1/Day 1

  2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of >450 msec in men and >470 msec in women

  3. Have a seizure disorder requiring anticonvulsant therapy

  4. Have untreated central nervous system (CNS) metastases including carcinomatous meningitis. Patients with definitively treated (radiotherapy or surgery) CNS metastases may be eligible if asymptomatic and not receiving corticosteroids in excess of prednisone 10 mg (or equivalent) per day for ≥2 weeks before first dose of TP-1454

  5. Have hypoxemia (defined as resting O2 saturation of ≤90% breathing room air)

  6. Have symptomatic interstitial lung disease or radiographic changes in the lungs that may make detection, diagnosis, or treatment of drug-induced pneumonitis difficult

  7. Have undergone major surgery within 2 weeks prior to Cycle 1/Day 1

  8. Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

  9. Are pregnant or nursing

  10. Received treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days or 5 half-lives, whichever occurs first, prior to study entry (6 weeks for nitrosoureas or mitomycin C)

  11. Are unwilling or unable to comply with procedures required in this protocol

  12. Have known infection with human immunodeficiency virus, hepatitis B, or hepatitis C. Patients with history of chronic hepatitis that is currently not active are eligible

  13. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor

  14. Are currently receiving any other investigational agent

  15. Have exhibited allergic reactions to a similar structural compound, biological agent, or formulation

  16. Have malabsorption conditions (eg, Crohn's disease, etc) or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption

  17. Require systemic corticosteroids greater than the equivalent of 10mg of prednisone or equivalent alternative steroid (except physiologic dose for adrenal replacement therapy) or other immunosuppressive agents (e.g., cyclosporine or methotrexate) (patients receiving combination therapy only)

  18. Have a history of malignancy within the past 24 months except curatively treated in situ cancers

  19. Have active, known, or suspected autoimmune disease with the exception of (patients receiving combination therapy only):

  • Type I diabetes mellitus

  • Hypothyroidism only requiring hormone replacement

  • Skin disorders not requiring systemic treatment, eg, vitiligo, alopecia, or psoriasis

  1. Have known EGFR mutations or ALK alterations that are sensitive to targeted therapy in NSCLC tumor types (patients receiving combination therapy only)

  2. Have ≥Grade 2 peripheral neuropathy (patients receiving combination therapy only)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic Arizona Phoenix Arizona United States 85054
2 University of Southern California - Norris Cancer Center and Hoag Memorial Hospital Los Angeles California United States 90033 and 92663
3 Mayo Clinic Jacksonville Jacksonville Florida United States 32224
4 Mayo Clinic Rochester Rochester Minnesota United States 55905
5 Comprehensive Cancer Center of Nevada Las Vegas Nevada United States 89169
6 Texas Oncology Baylor Sammons Cancer Center Dallas Texas United States 75246
7 Huntsman Cancer Institute Salt Lake City Utah United States 84112
8 University of Virginia Charlottesville Virginia United States 22908
9 Medical College of Wisconsin Milwaukee Wisconsin United States 53226

Sponsors and Collaborators

  • Sumitomo Pharma Oncology, Inc.

Investigators

  • Study Director: Gregory Pennock, MD, Sumitomo Pharma Oncology, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sumitomo Pharma Oncology, Inc.
ClinicalTrials.gov Identifier:
NCT04328740
Other Study ID Numbers:
  • TP-1454-101
First Posted:
Mar 31, 2020
Last Update Posted:
Apr 6, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sumitomo Pharma Oncology, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2022